Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Anthony Letai
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vivid
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Vivid is a start-up co-founded by Dr. Letai in 2018. Vivid is in the process of exclusively licensing from DFCI the BH3 profiling and dynamic BH3 profiling technology invented by Dr. Letai for use in the field of cancer. This project studies AML samples, cell lines, and murine primagrafts of AML with the overall goal of identifying drugs that induce death signaling in AML, and testing the ability to predict drug action in individual cases in vivo using BH3 profiling. The project aims to develop BH3 profiling as a predictive biomarker approach for single agents or drug combinations in AML. The results of this Work could be of scientific relevance to Vivid because it could demonstrate the effectiveness or ineffectiveness BH3 profiling as a predictive tool for evaluating therapeutic options. Given the early stage of Vivid, this work could directly and significantly impact the business direction of Vivid.
Development of Novel Therapeutic Strategies in Human Leukemias
RELEVANCE (See instructions): The overall goal of this program is to develop more effective and less toxic therapies for the treatment of leukemia. We will explore the targeting of epigenetic regulators, ubiquitin ligases, lysine acetyltransferases, and modulators of apoptotic threshold. Following pre-clinical studies in common model systems, the most promising therapies will be tested in clinical trials with deep molecular characterization of patient samples.
Filed on June 19, 2018.
Tell us what you know about Anthony Letai's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Anthony Letai”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Anthony Letai | Brigham and Women's Hospital | Conflict of Interest | Vivid | $20,000 - $39,999 |
| Anthony Letai | Dana Farber Cancer Inst | Conflict of Interest | Vivid Biosciences | Value cannot be readily determined |
| Anthony Letai | Dana Farber Cancer Inst | Conflict of Interest | Vivid Biosciences | Value cannot be readily determined |
| Anthony Letai | Dana Farber Cancer Inst | Conflict of Interest | Vivid Biosciences | $20,000 - $39,999 |
| Anthony Letai | Dana Farber Cancer Inst | Conflict of Interest | Vivid Biosciences | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.